Citigroup’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-104,573
| Closed | -$4.02M | – | 5875 |
|
|
2023
Q2 | $4.02M | Sell |
104,573
-43,237
| -29% | -$1.11M | ﹤0.01% | 1642 |
|
|
2023
Q1 | $3.42M | Buy |
147,810
+69,615
| +89% | +$1.66M | ﹤0.01% | 1695 |
|
|
2022
Q4 | $2.05M | Sell |
78,195
-53,812
| -41% | -$1.19M | ﹤0.01% | 2020 |
|
|
2022
Q3 | $2.6M | Buy |
132,007
+87,710
| +198% | +$1.76M | ﹤0.01% | 1953 |
|
|
2022
Q2 | $775K | Buy |
44,297
+29,457
| +198% | +$462K | ﹤0.01% | 2879 |
|
|
2022
Q1 | $243K | Sell |
14,840
-45,001
| -75% | -$612K | ﹤0.01% | 3973 |
|
|
2021
Q4 | $976K | Buy |
59,841
+24,957
| +72% | +$355K | ﹤0.01% | 3289 |
|
|
2021
Q3 | $445K | Sell |
34,884
-7,648
| -18% | -$101K | ﹤0.01% | 3685 |
|
|
2021
Q2 | $601K | Buy |
42,532
+40,846
| +2,423% | +$653K | ﹤0.01% | 3572 |
|
|
2021
Q1 | $26K | Sell |
1,686
-2,194
| -57% | -$35.8K | ﹤0.01% | 5101 |
|
|
2020
Q4 | $62K | Buy |
3,880
+3,242
| +508% | +$48.9K | ﹤0.01% | 5901 |
|
|
2020
Q3 | $8K | Sell |
638
-1,157
| -64% | -$15.5K | ﹤0.01% | 6791 |
|
|
2020
Q2 | $21K | Sell |
1,795
-2,151
| -55% | -$29.7K | ﹤0.01% | 6582 |
|
|
2020
Q1 | $54K | Buy |
3,946
+1,316
| +50% | +$15.6K | ﹤0.01% | 5929 |
|
|
2019
Q4 | $16K | Buy |
2,630
+854
| +48% | +$4.64K | ﹤0.01% | 7036 |
|
|
2019
Q3 | $9K | Sell |
1,776
-2,228
| -56% | -$14.8K | ﹤0.01% | 7147 |
|
|
2019
Q2 | $31K | Sell |
4,004
-1,056
| -21% | -$16.1K | ﹤0.01% | 6851 |
|
|
2019
Q1 | $101K | Buy |
5,060
+1,979
| +64% | +$34.5K | ﹤0.01% | 5740 |
|
|
2018
Q4 | $41K | Sell |
3,081
-17
| -0.5% | -$340 | ﹤0.01% | 6408 |
|
|
2018
Q3 | $114K | Buy |
+3,098
| New | +$99.5K | ﹤0.01% | 5774 |
|
|
2018
Q2 | – | Sell |
-46
| Closed | -$2K | – | 7787 |
|
|
2018
Q1 | $2K | Sell |
46
-11,427
| -100% | -$418K | ﹤0.01% | 7394 |
|
|
2017
Q4 | $430K | Buy |
11,473
+5,149
| +81% | +$225K | ﹤0.01% | 4255 |
|
|
2017
Q3 | $337K | Buy |
6,324
+6,270
| +11,611% | +$373K | ﹤0.01% | 4517 |
|
|
2017
Q2 | $3K | Sell |
54
-21
| -28% | -$1.05K | ﹤0.01% | 6921 |
|
|
2017
Q1 | $4K | Sell |
75
-7,999
| -99% | -$452K | ﹤0.01% | 6878 |
|
|
2016
Q4 | $460K | Buy |
8,074
+5,286
| +190% | +$320K | ﹤0.01% | 4459 |
|
|
2016
Q3 | $174K | Sell |
2,788
-72
| -3% | -$5.09K | ﹤0.01% | 4763 |
|
|
2016
Q2 | $162K | Sell |
2,860
-265
| -8% | -$16.1K | ﹤0.01% | 4687 |
|
|
2016
Q1 | $201K | Buy |
3,125
+914
| +41% | +$73.9K | ﹤0.01% | 5090 |
|
|
2015
Q4 | $311K | Buy |
2,211
+2,190
| +10,429% | +$297K | ﹤0.01% | 4326 |
|
|
2015
Q3 | $2K | Sell |
21
-1
| -5% | -$119 | ﹤0.01% | 7068 |
|
|
2015
Q2 | $3K | Buy |
+22
| New | +$3.63K | ﹤0.01% | 7038 |
|
Citigroup's KDNY Position: Q3 2023 in Review
Citigroup sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 104,573 shares — an estimated $4.02M sold.
Citigroup first reported a position in KDNY in Q2 2015 and held it in 32 quarters. The position peaked at $4.02M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- Citigroup reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Citigroup sold 104,573 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $4.02M.
- Citigroup first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 32 quarters.
- Citigroup's Chinook Therapeutics, Inc. Common Stock position peaked at $4.02M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on Citigroup's 13F filing for Q3 2023, filed 9 Nov 2023.